Abstract

This article explores the real-world evidence on the utilization of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the management of heart failure (HF), focusing on their efficacy and safety profiles across diverse patient populations. While randomized controlled trials have established the cardiovascular benefits of SGLT2 inhibitors, real-world data offer insights into their effectiveness and safety in routine clinical practice. Analysis of electronic health records, administrative claims databases, and other sources reveals consistent reductions in heart failure hospitalizations and cardiovascular mortality with SGLT2 inhibitor use. Importantly, these benefits extend across various subgroups, including elderly patients, individuals with comorbidities such as diabetes mellitus and chronic kidney disease, and diverse racial and ethnic backgrounds. Safety assessments underscore a favorable risk-benefit profile, with low incidences of serious adverse events. Overall, real-world evidence supports the integration of SGLT2 inhibitors into the treatment armamentarium for heart failure, emphasizing the need for personalized approaches to optimize patient outcomes